Trump’s sudden cut in substance testing is ‘going to kill people’, experts warn

# The SAMHSA Test Strip Ban Is a Public Health Betrayal That Will Kill Thousands When the Substance Abuse and Mental Health Services Administration (SAMHSA) issued its April 28 open letter to federal grantees, it did not just announce a bureaucratic funding restriction—it formalized a reckless, evidence-free policy shift that will directly fuel preventable overdose deaths across the United States. The directive bars all SAMHSA grant recipients from using federal funds to purchase or distribute fentanyl test strips, xylazine testing kits, or medetomidine screening tools, three critical resources for people navigating an illicit drug supply saturated with lethal synthetic substances. Administration officials framed the move as a deliberate “clear shift away from harm reduction” toward abstinence-focused treatment and long-term recovery support, but the policy ignores decades of peer-reviewed public health research and the lived reality of millions of people with substance use disorders. Fentanyl, a synthetic opioid 50 to 100 times more potent than morphine, is increasingly common in the U.S. illicit drug supply, and even small, unintended doses can cause fatal overdose. Xylazine, a veterinary sedative frequently cut into opioids to boost potency, causes severe necrotic wounds at injection sites and does not respond to standard naloxone doses, complicating emergency overdose response. Medetomidine, a newer veterinary drug with similar effects to xylazine, has already been detected in illicit supplies across 12 states as of early 2026, per Drug Enforcement Administration data. Peer-reviewed studies consistently find that access to fentanyl test strips reduces overdose risk by 30 to 40% among people who use drugs, with no correlation to increased substance use rates. Prior to the SAMHSA ban, federal grant funding supported the distribution of more than 10 million test strips annually to community harm reduction programs, tribal health organizations, and local health departments, per 2025 agency data, reaching people in 48 states and 17 tribal nations. The administration’s justification for the policy rests on the false claim that harm reduction measures normalize drug use and divert resources from “evidence-based” treatment. Its 2027 presidential budget proposal does include a 12% increase in funding for inpatient substance use treatment and recovery housing, which officials claim will offset the loss of test strip access. But this framing ignores a critical gap: only an estimated 20% of people with opioid use disorder receive any form of treatment in a given year, leaving millions without access to care. For many of these individuals, test strip distribution programs are the only point of contact they have with the health system, and a low-stakes entry point to connect to treatment resources if and when they are ready to seek help. The policy will take effect on July 1, 2026, and its disparate impact on Indigenous communities is already drawing alarm from tribal health leaders: overdose rates in Native communities are 2.5 times the national average, and most tribal health programs rely exclusively on SAMHSA funding to distribute test strips. While states including California, New York, and Colorado have allocated state funding to expand test strip access in recent years, state budgets cannot cover the full gap left by the loss of federal support. Advocates are now lobbying Congress to include a provision blocking the restriction in upcoming must-pass government funding legislation, though the administration has signaled it will veto any such measure. This is not a policy shift toward treatment. It is a deliberate abandonment of evidence-based public health practice, and a choice that will cost thousands of lives.